Status:
COMPLETED
Seroprevalence of IgG Antibodies to SARS-CoV-2 (COVID-19) in Primary Health Care Workers and Their Household Contacts
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Covid19
Eligibility:
All Genders
Phase:
NA
Brief Summary
Many uncertainties remain regarding the epidemiological and clinical characteristics of COVID-19, including the number of people exposed to the disease, the persistence of the humoral response and its...
Detailed Description
Primary endpoint \- Estimation of the prevalence of healthcare professionals with IgG antibodies to SARS-CoV-2 in each of the four study populations (general practitioners, paediatricians, healthcare...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Health professionals in primary care :
- General practitioners, paediatricians, pharmacists, pharmacy assistants, dental surgeons or dental assistants practising in metropolitan France at the time of inclusion (condition ensured by affiliation to one of the four networks);
- Be affiliated to one of the following networks: Sentinelles, AFPA, IQVIA, ReCOL or work in a city pharmacy (for pharmacy assistants) or in a dental practice (dental assistants) whose owners are affiliated to these networks;
- To be a volunteer to participate in the study;
- To have given their agreement in principle to the collection of data (including personal data) necessary for recruitment;
- Have given their consent to participate in the study;
- To be affiliated to a social security scheme or to be a beneficiary of such a scheme.
- Members of health professionals' households :
- Occupy the same dwelling as a healthcare professional included in PHASE 1 of the COVID-SeroPRIM study at least 2 days per week (including weekend attendees, every other week, etc.) at the time of inclusion in the study, without necessarily being related;
- To have volunteered to participate in the study;
- To have given their consent to participate in the study or, in the case of minors, consent given by the representative(s) of the parental authority;
- To be able to understand the study process, to fill in the questionnaires and to take the planned samples (if the person included is old enough to understand).
- Exclusion criteria :
- Persons subject to a legal protection measure (safeguard of justice, curatorship, guardianship);
- Persons who have participated in clinical trials to test chemoprophylaxis to prevent infection with SARS-CoV-2.
- Minors who do not have a parent or guardian in the health professional's household
Exclusion
Key Trial Info
Start Date :
May 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 12 2021
Estimated Enrollment :
2817 Patients enrolled
Trial Details
Trial ID
NCT04808986
Start Date
May 10 2021
End Date
October 12 2021
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Pierre Louis Epidemiologie Et Sante Publique
Paris, France, 75012